Market research
RHY.AU Rhythm Biosciences Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 31M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.41
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- AU000000RHY2
- Market cap
- 31M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.41
About
About Rhythm Biosciences Limited
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RHY.AU discussion.
5 years, 5 months ago
Rhythm Biosciences Limited is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Rhythm Biosciences Limited's total revenue sank by 60.3% to $10K since the same quarter in the previous year.
Its net income has dropped by 5.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 51.0% to $-770K since the same quarter in the previous year.
Based on the above factors, Rhythm Biosciences Limited gets an overall score of 1/5.